FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201715512> ?p ?o ?g. }

• W3201715512 endingPage "e2127369" @default.
• W3201715512 startingPage "e2127369" @default.
• W3201715512 abstract "Persons with kidney failure require treatment (ie, dialysis or transplantation) for survival. The burden of the COVID-19 pandemic and pandemic-related disruptions in care have disproportionately affected racial and ethnic minority and socially disadvantaged populations, raising the importance of understanding disparities in treatment initiation for kidney failure during the pandemic.To examine changes in the number and demographic characteristics of patients initiating treatment for incident kidney failure following the COVID-19 pandemic by race and ethnicity, county-level COVID-19 mortality rate, and neighborhood-level social disadvantage.This cross-sectional time-trend study used data from US patients who developed kidney failure between January 1, 2018, and June 30, 2020. Data were analyzed between January and July 2021.COVID-19 pandemic.Number of patients initiating treatment for incident kidney failure and mean estimated glomerular filtration rate (eGFR) at treatment initiation.The study population included 127 149 patients with incident kidney failure between January 1, 2018, and June 30, 2020 (mean [SD] age, 62.8 [15.3] years; 53 021 [41.7%] female, 32 932 [25.9%] non-Hispanic Black, and 19 835 [15.6%] Hispanic/Latino patients). Compared with the pre-COVID-19 period, in the first 4 months of the pandemic (ie, March 1 through June 30, 2020), there were significant decreases in the proportion of patients with incident kidney failure receiving preemptive transplantation (1805 [2.1%] pre-COVID-19 vs 551 [1.4%] during COVID-19; P < .001) and initiating hemodialysis treatment with an arteriovenous fistula (2430 [15.8%] pre-COVID-19 vs 914 [13.4%] during COVID-19; P < .001). The mean (SD) eGFR at initiation declined from 9.6 (5.0) mL/min/1.73 m2 to 9.5 (4.9) mL/min/1.73 m2 during the pandemic (P < .001). In stratified analyses by race/ethnicity, these declines were exclusively observed among non-Hispanic Black patients (mean [SD] eGFR: 8.4 [4.6] mL/min/1.73 m2 pre-COVID-19 vs 8.1 [4.5] mL/min/1.73 m2 during COVID-19; P < .001). There were significant declines in eGFR at initiation for patients residing in counties in the highest quintile of COVID-19 mortality rates (9.5 [5.0] mL/min/1.73 m2 pre-COVID-19 vs 9.2 [5.0] mL/min/1.73 m2 during COVID-19; P < .001), but not for patients residing in other counties. The number of patients initiating treatment for incident kidney failure was approximately 30% lower than projected in April 2020.In this cross-sectional study of US adults, the COVID-19 pandemic was associated with a substantially lower number of patients initiating treatment for incident kidney failure and treatment initiation at lower levels of kidney function during the first 4 months, particularly for Black patients and people living in counties with high COVID-19 mortality rates." @default.
• W3201715512 created "2021-10-11" @default.
• W3201715512 creator A5020766514 @default.
• W3201715512 creator A5021840981 @default.
• W3201715512 creator A5025116275 @default.
• W3201715512 creator A5025228232 @default.
• W3201715512 creator A5026575460 @default.
• W3201715512 creator A5028516688 @default.
• W3201715512 creator A5036202898 @default.
• W3201715512 creator A5073716549 @default.
• W3201715512 creator A5073871253 @default.
• W3201715512 creator A5085480399 @default.
• W3201715512 date "2021-10-07" @default.
• W3201715512 modified "2023-10-18" @default.
• W3201715512 title "Evaluation of Racial, Ethnic, and Socioeconomic Disparities in Initiation of Kidney Failure Treatment During the First 4 Months of the COVID-19 Pandemic" @default.
• W3201715512 cites W2000353468 @default.
• W3201715512 cites W2016615097 @default.
• W3201715512 cites W2032046156 @default.
• W3201715512 cites W2052083565 @default.
• W3201715512 cites W2112983108 @default.
• W3201715512 cites W2147619266 @default.
• W3201715512 cites W2155965977 @default.
• W3201715512 cites W2589053692 @default.
• W3201715512 cites W2607031541 @default.
• W3201715512 cites W2772994420 @default.
• W3201715512 cites W2810551427 @default.
• W3201715512 cites W2898242607 @default.
• W3201715512 cites W2900316531 @default.
• W3201715512 cites W2943217266 @default.
• W3201715512 cites W2963191841 @default.
• W3201715512 cites W3014452322 @default.
• W3201715512 cites W3020954032 @default.
• W3201715512 cites W3023692003 @default.
• W3201715512 cites W3024464227 @default.
• W3201715512 cites W3028782977 @default.
• W3201715512 cites W3031297436 @default.
• W3201715512 cites W3033776099 @default.
• W3201715512 cites W3034003 @default.
• W3201715512 cites W3036766640 @default.
• W3201715512 cites W3036987516 @default.
• W3201715512 cites W3042648119 @default.
• W3201715512 cites W3046321541 @default.
• W3201715512 cites W3092292894 @default.
• W3201715512 cites W3093625694 @default.
• W3201715512 cites W3095683608 @default.
• W3201715512 cites W3109422208 @default.
• W3201715512 cites W3110492358 @default.
• W3201715512 cites W3111680854 @default.
• W3201715512 cites W3121997698 @default.
• W3201715512 cites W3130566720 @default.
• W3201715512 cites W3131637887 @default.
• W3201715512 cites W3148585724 @default.
• W3201715512 cites W4243892001 @default.
• W3201715512 doi "https://doi.org/10.1001/jamanetworkopen.2021.27369" @default.
• W3201715512 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8498850" @default.
• W3201715512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34618039" @default.
• W3201715512 hasPublicationYear "2021" @default.
• W3201715512 type Work @default.
• W3201715512 sameAs 3201715512 @default.
• W3201715512 citedByCount "11" @default.
• W3201715512 countsByYear W32017155122021 @default.
• W3201715512 countsByYear W32017155122022 @default.
• W3201715512 countsByYear W32017155122023 @default.
• W3201715512 crossrefType "journal-article" @default.
• W3201715512 hasAuthorship W3201715512A5020766514 @default.
• W3201715512 hasAuthorship W3201715512A5021840981 @default.
• W3201715512 hasAuthorship W3201715512A5025116275 @default.
• W3201715512 hasAuthorship W3201715512A5025228232 @default.
• W3201715512 hasAuthorship W3201715512A5026575460 @default.
• W3201715512 hasAuthorship W3201715512A5028516688 @default.
• W3201715512 hasAuthorship W3201715512A5036202898 @default.
• W3201715512 hasAuthorship W3201715512A5073716549 @default.
• W3201715512 hasAuthorship W3201715512A5073871253 @default.
• W3201715512 hasAuthorship W3201715512A5085480399 @default.
• W3201715512 hasBestOaLocation W32017155121 @default.
• W3201715512 hasConcept C126322002 @default.
• W3201715512 hasConcept C137403100 @default.
• W3201715512 hasConcept C144024400 @default.
• W3201715512 hasConcept C147077947 @default.
• W3201715512 hasConcept C149923435 @default.
• W3201715512 hasConcept C19165224 @default.
• W3201715512 hasConcept C2778063415 @default.
• W3201715512 hasConcept C2779134260 @default.
• W3201715512 hasConcept C2779978075 @default.
• W3201715512 hasConcept C2780303639 @default.
• W3201715512 hasConcept C2908647359 @default.
• W3201715512 hasConcept C2911091166 @default.
• W3201715512 hasConcept C3008058167 @default.
• W3201715512 hasConcept C524204448 @default.
• W3201715512 hasConcept C71924100 @default.
• W3201715512 hasConcept C89623803 @default.
• W3201715512 hasConcept C99454951 @default.
• W3201715512 hasConceptScore W3201715512C126322002 @default.
• W3201715512 hasConceptScore W3201715512C137403100 @default.
• W3201715512 hasConceptScore W3201715512C144024400 @default.
• W3201715512 hasConceptScore W3201715512C147077947 @default.
• W3201715512 hasConceptScore W3201715512C149923435 @default.
• W3201715512 hasConceptScore W3201715512C19165224 @default.

• next